EBT-101是一种独特的基于CRISPR的体内疗法,旨在通过单次静脉输注治愈HIV感染。EBT-101采用腺相关病毒(AAV)来传递CRISPR-Cas9和双向导RNA,从而实现多重体内编辑方法,同时靶向HIV基因组内的三个不同位点。这允许切除大部分HIV基因组,从而最大限度地减少潜在的HIV逃逸。 关于EBT-101临床计划 EBT-101 1/2 期试验是一...
EBT-101由美国坦普尔大学Lewis Katz医学院和Excision BioTherapeutics共同开发，其本质是一种基因疗法。在被注射进入人体后，通过利用一种腺相关病毒（AAV）传递CRISPR-Cas9和双导向RNA，它将针对HIV基因组中三个不同点位进行多重编辑，从而切除大部分HIV基因组，最大限度地减少潜在的病毒逃逸。其中的CRISPR-Cas9值得特别...
“Excision is dedicated to developing curative, CRISPR-based therapies for people with infectious disease,” said Daniel Dornbusch, Chief Executive Officer of Excision. “EBT-101 is a CRISPR-based gene therapy ...
EBT-101 is a unique,in vivoCRISPR-based therapeutic designed to cure HIV infections with a single treatment. Excision’s pipeline unites next-generation CRISPR nucleases with a novel gene editing approach to remove HIV proviral DNA...
Excision BioTherapeutics, Inc. recently announced the first participant has been dosed in the Phase 1/2 clinical trial of EBT-101 for human immunodeficiency virus type 1 (HIV-1)...